These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26479699)

  • 1. The TZD insulin sensitizer clue provides a new route into diabetes drug discovery.
    Colca JR
    Expert Opin Drug Discov; 2015 Dec; 10(12):1259-70. PubMed ID: 26479699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--relationship to newly identified mitochondrial pyruvate carrier proteins.
    Colca JR; McDonald WG; Cavey GS; Cole SL; Holewa DD; Brightwell-Conrad AS; Wolfe CL; Wheeler JS; Coulter KR; Kilkuskie PM; Gracheva E; Korshunova Y; Trusgnich M; Karr R; Wiley SE; Divakaruni AS; Murphy AN; Vigueira PA; Finck BN; Kletzien RF
    PLoS One; 2013; 8(5):e61551. PubMed ID: 23690925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism.
    Vigueira PA; McCommis KS; Hodges WT; Schweitzer GG; Cole SL; Oonthonpan L; Taylor EB; McDonald WG; Kletzien RF; Colca JR; Finck BN
    Exp Physiol; 2017 Aug; 102(8):985-999. PubMed ID: 28597936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases.
    Colca JR; Tanis SP; McDonald WG; Kletzien RF
    Expert Opin Investig Drugs; 2014 Jan; 23(1):1-7. PubMed ID: 24073940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances on PPARγ Research in the Emerging Era of Precision Medicine.
    Lu P; Zhao Z
    Curr Drug Targets; 2018; 19(6):663-673. PubMed ID: 28641522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolidinedione compounds: a patent review (2010 - present).
    Desai NC; Pandit UP; Dodiya A
    Expert Opin Ther Pat; 2015 Apr; 25(4):479-88. PubMed ID: 25579106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE; Hanna A
    Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action.
    Zierath JR; Ryder JW; Doebber T; Woods J; Wu M; Ventre J; Li Z; McCrary C; Berger J; Zhang B; Moller DE
    Endocrinology; 1998 Dec; 139(12):5034-41. PubMed ID: 9832442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes.
    Leibowitz MD; Ardecky RJ; Boehm MF; Broderick CL; Carfagna MA; Crombie DL; D'Arrigo J; Etgen GJ; Faul MM; Grese TA; Havel H; Hein NI; Heyman RA; Jolley D; Klausing K; Liu S; Mais DE; Mapes CM; Marschke KB; Michellys PY; Montrose-Rafizadeh C; Ogilvie KM; Pascual B; Rungta D; Tyhonas JS; Urcan MS; Wardlow M; Yumibe N; Reifel-Miller A
    Endocrinology; 2006 Feb; 147(2):1044-53. PubMed ID: 16269450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J; Morales M; Caelles C
    Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPARγ ligands and their therapeutic applications: a patent review (2008 - 2014).
    Takada I; Makishima M
    Expert Opin Ther Pat; 2015 Feb; 25(2):175-91. PubMed ID: 25416646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiazolidinediones and PPARγ agonists: time for a reassessment.
    Cariou B; Charbonnel B; Staels B
    Trends Endocrinol Metab; 2012 May; 23(5):205-15. PubMed ID: 22513163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinedione safety.
    Kung J; Henry RR
    Expert Opin Drug Saf; 2012 Jul; 11(4):565-79. PubMed ID: 22616948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus.
    Stefanović V; Antić S
    Clin Lab; 2004; 50(5-6):271-8. PubMed ID: 15209435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adiponectin increases insulin content and cell proliferation in MIN6 cells via PPARγ-dependent and PPARγ-independent mechanisms.
    Rao JR; Keating DJ; Chen C; Parkington HC
    Diabetes Obes Metab; 2012 Nov; 14(11):983-9. PubMed ID: 22594400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.